For the quarter ending 2025-09-30, DNA had -$94,391K decrease in cash & cash equivalents over the period. -$31,606K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -232,012 | - |
| Depreciation and amortization | 14,168 | 31,159 |
| Stock-based compensation | 17,841 | 42,678 |
| Goodwill impairment | 0 | 0 |
| Impairment of right-of-use asset | 0 | 0 |
| Loss on investments | 3,683 | -3,958 |
| Loss on deconsolidation of subsidiary | 0 | - |
| Change in fair value of notes receivable | -400 | -5,285 |
| Change in fair value of warrant liabilities | 0 | 0 |
| Change in fair value of contingent consideration | 0 | 4,232 |
| Non-cash lease expense | 7,583 | 14,866 |
| Non-cash in-process research and development | 0 | 0 |
| Net loss | - | -151,257 |
| Accretion of discount on marketable securities | 2,502 | - |
| Other non-cash activity | -1,565 | -46 |
| Changes in operating assets and liabilities | -757 | 412 |
| Prepaid expenses and other current assets | -2,202 | 2,272 |
| Operating lease right-of-use assets | 0 | -3,814 |
| Other non-current assets | -87 | 125 |
| Accounts payable, accrued expenses and other current liabilities | 22,116 | -5,125 |
| Deferred revenue | -3,533 | -23,676 |
| Operating lease liabilities, current and non-current | -7,155 | -11,638 |
| Other non-current liabilities | -697 | 5,156 |
| Net cash used in operating activities | -31,606 | -91,775 |
| Purchases of marketable debt securities | 81,706 | 320,132 |
| Maturities of marketable debt securities | 73,599 | - |
| Purchases of property and equipment | 0 | 7,660 |
| Business acquisition | 0 | 0 |
| Proceeds from sales of marketable securities | -64,958 | 64,958 |
| Proceeds from sale of equipment | 0 | - |
| Other | -249 | -262 |
| Net cash used in investing activities | -72,816 | -262,572 |
| Proceeds from atm offering | 10,317 | - |
| Payment of issuance costs related to atm offering | 355 | - |
| Proceeds from exercise of stock options | 0 | 0 |
| Principal payments on finance leases | 24 | 305 |
| Contingent consideration payment | 0 | 0 |
| Other | 0 | - |
| Net cash provided by (used in) financing activities | 9,938 | -305 |
| Effect of foreign exchange rates on cash and cash equivalents | 93 | 260 |
| Net decrease in cash, cash equivalents and restricted cash | -94,391 | -354,392 |
| Cash and cash equivalents at beginning of period | 605,743 | - |
| Cash and cash equivalents at end of period | 156,960 | - |
Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. (DNA)